Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
letter
. 2020 Aug 28;64(3):482–485. doi: 10.1007/s11427-020-1805-0

Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge

Huan Ma 1,2,#, Dan Zhao 2,#, Weihong Zeng 1,2,#, Yunru Yang 2, Xiaowen Hu 3, Peigen Zhou 4, Jianping Weng 1,5,6, Linzhao Cheng 7,8, Xueying Zheng 1,5,6,✉, Tengchuan Jin 1,2,9,✉
PMCID: PMC7463100  PMID: 32876887

The content is available as a PDF (885.6 KB).

Acknowledgements

We thank the staff and patients in The First Affiliated Hospital of USTC for their support in providing samples and clinical data collection. We would also like to thank Prof. Tian Xue and other colleagues in Division of Life Sciences and Medicine for their generous and professional support. T.J. is supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030104), National Natural Science Foundation of China (31870731 and U1732109), the Fundamental Research Funds for the Central Universities (WK2070000108) and a COVID-19 special task grant supported by Chinese Academy of Sciences Clinical Research Hospital (Hefei) with Grant No. YD2070002017. M.H. is supported by the new medical science fund of University of Science and Technology of China (WK2070000130). J.W. and X.Y. are supported by the Fundamental Research Funds for the Central Universities with Grant Nos. YD9110004001 and YD9110002002, respectively.

Supplemental Materials for

11427_2020_1805_MOESM1_ESM.pdf (499.2KB, pdf)

Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge

Footnotes

Compliance and ethics

The author(s) declare that they have no conflict of interest. This study was reviewed and approved by the Medical Ethical Committee of First Affiliated Hospital of USTC (approval number 2020-XG (H)-014 and 2020-XG(H)-009).

Contributed equally to this work

Contributor Information

Xueying Zheng, Email: lxyzheng@ustc.edu.cn.

Tengchuan Jin, Email: jint@ustc.edu.cn.

References

  1. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357:1162–1163. doi: 10.1056/NEJMc070348. [DOI] [PubMed] [Google Scholar]
  2. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z. [DOI] [PubMed] [Google Scholar]
  4. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–1204. doi: 10.1038/s41591-020-0965-6. [DOI] [PubMed] [Google Scholar]
  5. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, Cheng L, Li Y, Ma X, Jin T. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17:773–775. doi: 10.1038/s41423-020-0474-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, Wei P, Ge J, Gou M, Li X, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52:971–977.e3. doi: 10.1016/j.immuni.2020.04.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442. doi: 10.1038/s41586-020-2456-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Teunis PFM, van Eijkeren JCH, de Graaf WF, Marinović AB, Kretzschmar MEE. Linking the seroresponse to infection to within-host heterogeneity in antibody production. Epidemics. 2016;16:33–39. doi: 10.1016/j.epidem.2016.04.001. [DOI] [PubMed] [Google Scholar]
  9. Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020). Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv, 10.1101/2020.03.30.20047365.
  10. Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., et al. (2020). Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. JAMA 10.1001/jama.2020.15543. [DOI] [PMC free article] [PubMed]

Articles from Science China. Life Sciences are provided here courtesy of Nature Publishing Group

RESOURCES